Management of alcohol withdrawal delirium. An evidence-based practice guideline
- PMID: 15249349
- DOI: 10.1001/archinte.164.13.1405
Management of alcohol withdrawal delirium. An evidence-based practice guideline
Erratum in
- Arch Intern Med. 2004 Oct 11;164(18):2068. Dosage error in article text
Abstract
Background: Alcohol withdrawal delirium is the most serious manifestation of alcohol withdrawal. Evidence suggests that appropriate care improves mortality, but systematic reviews are unavailable.
Methods: Articles with original data on management of alcohol withdrawal delirium underwent structured review and meta-analysis.
Results: Meta-analysis of 9 prospective controlled trials demonstrated that sedative-hypnotic agents are more effective than neuroleptic agents in reducing duration of delirium and mortality, with a relative risk of death when using neuroleptic agents of 6.6. Statistically significant differences among various benzodiazepines and barbiturates were not found. No deaths were reported in 217 patients from trials using benzodiazepines or barbiturates.
Conclusions: Control of agitation should be achieved using parenteral rapid-acting sedative-hypnotic agents that are cross-tolerant with alcohol. Adequate doses should be used to maintain light somnolence for the duration of delirium. Coupled with comprehensive supportive medical care, this approach is highly effective in preventing morbidity and mortality.
Comment in
-
Review: sedative-hypnotic agents reduce mortality and duration of delirium in the alcohol withdrawal syndrome.ACP J Club. 2005 Jan-Feb;142(1):4. ACP J Club. 2005. PMID: 15656545 No abstract available.
-
Pharmacotherapy of alcohol withdrawal delirium in patients admitted to a general hospital.Arch Intern Med. 2005 Feb 14;165(3):346. doi: 10.1001/archinte.165.3.346-a. Arch Intern Med. 2005. PMID: 15710803 No abstract available.
-
Alcohol withdrawal delirium.Arch Intern Med. 2005 Mar 14;165(5):586; author reply 587. doi: 10.1001/archinte.165.5.586-b. Arch Intern Med. 2005. PMID: 15767537 No abstract available.
-
Baclofen use in the treatment of alcohol delirium tremens.Arch Intern Med. 2005 Mar 14;165(5):586; author reply 587. doi: 10.1001/archinte.165.5.586-a. Arch Intern Med. 2005. PMID: 15767538 No abstract available.
-
Treatment of delirium tremens.Arch Intern Med. 2005 Mar 14;165(5):587; author reply 587. doi: 10.1001/archinte.165.5.587-a. Arch Intern Med. 2005. PMID: 15767540 No abstract available.
Similar articles
-
Alcohol withdrawal syndrome: how to predict, prevent, diagnose and treat it.Prescrire Int. 2007 Feb;16(87):24-31. Prescrire Int. 2007. PMID: 17323538
-
Treatment of terminal restlessness: a review of the evidence.J Pain Palliat Care Pharmacother. 2004;18(1):5-30. J Pain Palliat Care Pharmacother. 2004. PMID: 15148006 Review.
-
Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal.JAMA. 1997 Jul 9;278(2):144-51. doi: 10.1001/jama.278.2.144. JAMA. 1997. PMID: 9214531
-
Valproic acid management of acute alcohol withdrawal.Ann Pharmacother. 2006 Mar;40(3):441-8. doi: 10.1345/aph.1G243. Epub 2006 Feb 28. Ann Pharmacother. 2006. PMID: 16507623 Review.
-
[Treatment of alcohol withdrawal symptoms with benzodiazepines].Ugeskr Laeger. 2006 Aug 28;168(35):2896-9. Ugeskr Laeger. 2006. PMID: 16982018 Review. Danish. No abstract available.
Cited by
-
SIRS criteria versus qSOFA score in patients with severe alcohol-related hepatitis.Intern Emerg Med. 2024 Oct 11. doi: 10.1007/s11739-024-03786-2. Online ahead of print. Intern Emerg Med. 2024. PMID: 39392538
-
Replacing the Clinical Institute Withdrawal Assessment-Alcohol revised with the modified Richmond Agitation and Sedation Scale for alcohol withdrawal to support management of alcohol withdrawal symptoms: potential impact on length of stay and complications.CJEM. 2024 Jun;26(6):431-435. doi: 10.1007/s43678-024-00710-7. Epub 2024 May 26. CJEM. 2024. PMID: 38796808
-
Hovenia dulcis: a Chinese medicine that plays an essential role in alcohol-associated liver disease.Front Pharmacol. 2024 Apr 8;15:1337633. doi: 10.3389/fphar.2024.1337633. eCollection 2024. Front Pharmacol. 2024. PMID: 38650630 Free PMC article. Review.
-
ACG Clinical Guideline: Alcohol-Associated Liver Disease.Am J Gastroenterol. 2024 Jan 1;119(1):30-54. doi: 10.14309/ajg.0000000000002572. Epub 2023 Sep 1. Am J Gastroenterol. 2024. PMID: 38174913
-
Closing the Care Gap: Management of Alcohol Use Disorder in Patients with Alcohol-associated Liver Disease.Clin Ther. 2023 Dec;45(12):1189-1200. doi: 10.1016/j.clinthera.2023.09.017. Epub 2023 Dec 4. Clin Ther. 2023. PMID: 38052695 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
